InsidersTradesSigma
Follow the 昊海生科 stock price and the full insider trade history of the company, a listed equity based in China. Shares are listed on the CN market, under the authority of SSE / SZSE (CSRC). Operating in the Health Care sector, 昊海生科 has logged 8 reports. Market capitalisation: €6.9bn. The latest transaction was reported on 29 June 2026 (Sale). Among the most active insiders: 甘人宝. Every trade is free.
8
Insider Decl.
n/a
Thresholds
€9,949
1 ops.
Buy Volume
€3m
7 ops.
Sell Volume
4Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 10,269 of 28,803 companies
58.7
score / 100
Value52
Quality65
FCF yld4.6%
Earn yld3.8%
EV/EBITDA15.1x
ROE2.1%
Gross mgn70%
Net mgn10%
Debt/EBITDA0.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 29 June 2026
Declarations8 total
8 of 8 declarations
About 昊海生科
昊海生科 is a company in the health and pharmaceutical sector, listed on the XSHG market. It focuses on the development and production of innovative pharmaceutical products.